Urogen Pharma (URGN) Projected to Post Earnings on Monday

Urogen Pharma (NASDAQ:URGN) is anticipated to issue its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($0.65) per share and revenue of $39.9220 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 2, 2026 at 10:00 AM ET.

Urogen Pharma Price Performance

Shares of Urogen Pharma stock opened at $21.70 on Monday. The stock has a market cap of $1.02 billion, a PE ratio of -6.27 and a beta of 1.34. The firm has a fifty day moving average price of $21.28 and a 200 day moving average price of $20.89. Urogen Pharma has a 1 year low of $3.42 and a 1 year high of $30.00.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on URGN. Wall Street Zen raised Urogen Pharma from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. D. Boral Capital reiterated a “buy” rating and set a $33.00 price target on shares of Urogen Pharma in a research report on Friday, January 23rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, January 21st. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $33.29.

Insider Activity at Urogen Pharma

In other news, insider Mark Schoenberg sold 7,373 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total value of $145,174.37. Following the completion of the sale, the insider directly owned 144,985 shares in the company, valued at $2,854,754.65. The trade was a 4.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Jason Drew Smith sold 7,479 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total value of $147,261.51. Following the transaction, the general counsel directly owned 51,326 shares of the company’s stock, valued at approximately $1,010,608.94. The trade was a 12.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 4.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Urogen Pharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC increased its stake in shares of Urogen Pharma by 347.5% during the first quarter. AQR Capital Management LLC now owns 114,066 shares of the company’s stock worth $1,262,000 after purchasing an additional 88,577 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Urogen Pharma by 7.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after buying an additional 1,653 shares during the last quarter. Jane Street Group LLC boosted its holdings in Urogen Pharma by 94.3% in the 1st quarter. Jane Street Group LLC now owns 51,177 shares of the company’s stock worth $566,000 after buying an additional 24,839 shares during the last quarter. Cetera Investment Advisers purchased a new stake in Urogen Pharma during the 2nd quarter worth approximately $361,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of Urogen Pharma by 5.2% during the second quarter. JPMorgan Chase & Co. now owns 390,364 shares of the company’s stock valued at $5,348,000 after acquiring an additional 19,405 shares during the last quarter. 91.29% of the stock is owned by hedge funds and other institutional investors.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.